Unlocking the full potential of immunopeptidomics with the timsTOF Ultra
1 1 people viewed this event.
Overview
Alithea Biotechnology was founded in 2019 by Fanny Giannou and Tim Fugmann to support Biopharma globally on the development of innovative therapies targeting HLA-presented peptides. Alithea has a significant track record in the absolute quantification of HLA peptides, off-target toxicity predictions and target discovery. In addition, HLA-Compass is Alithea’s cloud-accessible HLA peptide database featuring the measurement of a total of 1.4 Million HLA peptides in 4160 healthy tissue, tumor tissue and cancer cell line samples for target validation and off-target toxicity prediction.
Why to join this webinar:
- The timsTOF Ultra can lead to high quality immunopeptidomes from limited sample
- Extensive HLA databases can significantly speed up the T-Cell-Receptor therapy development process
- The time is ripe to bring immunopeptidomics into clinical routine